Document is current
Any future updates will be listed below
-
Authors
Póvoa, Pedro https://orcid.org/0000-0002-7069-7304
Coelho, Luís https://orcid.org/0000-0003-0701-3624
Cidade, José Pedro https://orcid.org/0000-0002-9538-8487
Ceccato, Adrian https://orcid.org/0000-0001-9454-062X
Morris, Andrew Conway https://orcid.org/0000-0002-3211-3216
Salluh, Jorge https://orcid.org/0000-0002-8164-1453
Nobre, Vandack https://orcid.org/0000-0002-7922-0422
Nseir, Saad https://orcid.org/0000-0002-7618-0357
Martin-Loeches, Ignacio https://orcid.org/0000-0002-5834-4063
Lisboa, Thiago https://orcid.org/0000-0003-4306-2212
Ramirez, Paula https://orcid.org/0000-0002-7598-3350
Rouzé, Anahita https://orcid.org/0000-0002-1330-3161
Sweeney, Daniel A. https://orcid.org/0000-0002-5398-3528
Kalil, Andre C. https://orcid.org/0000-0002-6489-6294
- License Information
-
More Information
Article History
Received: 12 March 2024
Accepted: 27 May 2024
First Online: 17 July 2024
Declarations
:
: Not applicable.
: All the authors read and approved the manuscript.
: PP Lectures: Gilead, Pfizer, Mundipharma, MSD and Advisory board: Biocodex, Gilead; ACM Lectures: Thermo-Fisher, Biomerieux, Fischer and Paykel and Boston Scientific and Advisory board: Cambridge Infection Diagnostics; supported by an MRC Clinician Scientist Fellowship (MR/V006118/1); SN Lectures and Advisory Board: Pfizer, MSD, Biomérieux, Mundi Pharma, Medtronic, Fisher and Peykel; IML Lectures: Gilead, Thermofisher, Pfizer, MSD, Menarini and Advisory board: Fresenius Kabi, Advanz Pharma, Gilead, Accelerate, MSD; PR Lectures: Pfizer, MSD, Gilead, Novartis, Shionogi; AR Lectures: MSD, Gilead, Mundipharma; LC, JPC, AC, JS, VN, TL, DAS, ACK declare no COI.
